First Subject Enrolled in Trial of Medtronic’s Liquid Embolic System

JenaValve’s ARTIST RCT of Trilogy System in AR Begins Enrollment - Cardiac Interventions Today

July 17, 2025—JenaValve Technology, Inc. recently announced commencement of patient enrollment in both the transcatheter aortic valve replacement (TAVR) arm and the surgical aortic valve replacement (SAVR) arm of the ARTIST randomized controlled trial. According to the company, ARTIST is evaluating the safety and effectiveness of TAVR with the company’s Trilogy transcatheter heart valve (THV) system compared to SAVR in patients with aortic regur…

First subject enrolled in trial of Medtronic’s liquid embolic system

Medtronic has announced the first subject enrolment in the PELE trial, aiming to assess the Onyx liquid embolic system (LES).The post First subject enrolled in trial of Medtronic’s liquid embolic system appeared first on Medical Device Network.

Medtronic enrolls first patient in IDE study for Onyx LES

The Onyx LES offering. [Image courtesy of Medtronic] Medtronic [WtwhTicker symbol=”MDT”](NYSE: MDT)[/WtwhTicker] today announced the first patient enrolled in the PELE trial of its Onyx liquid embolic system (LES). PELE (Peripheral Onyx Liquid Embolic) evaluates the safety of Onyx LES for the embolization of arterial hemorrhage in the peripheral vasculature. Dr. Christopher Stark performed the first procedure at Albany Medical Center. Onyx LES, …

Medtronic enrols first patient in Onyx liquid embolic IDE clinical study - Interventional News

Medtronic today announced that the first patient has been enrolled in the Peripheral Onyx liquid embolic (PELE) clinical trial, which will evaluate the safety and effectiveness of the Onyx liquid embolic system (LES) for embolisation of arterial haemorrhage in the peripheral vasculature. The first procedure was performed by Christopher Stark at Albany Medical Center (Albany, USA). Data from the PELE investigational device exemption (IDE) clinica…